Mirum Pharmaceuticals Stock Quote MIRM - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

23.57

Bid

23.15

Ask

24.90

Volume

400,347

23.29 Day's Range 24.06

23.29 52 Week Range 35.56

Market Cap

1.099B

Previous Close

23.85

Open

23.73

Last Trade

23.15

Last Trade Time

Financial Volume

$ 9,460,413

VWAP

23.6305

Average Volume (3m)

507,543

Shares Outstanding

46,614,274

Dividend Yield

PE Ratio

-6.73

Earnings Per Share (EPS)

-3.51

Revenue

186.37M

Net Profit

-163.42M

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Dover, Delaware, USA

Founded

1970

Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $23.85. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.29 to $ 35.56.

Mirum Pharmaceuticals currently has 46,614,274 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.10 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.73.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - LIVMARLI is the first and only...

LIVMARLI (solution orale de maralixibat) de Mirum Pharmaceuticals reçoit une recommandation de remboursement positive de l’ACMTS du Canada pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille

- Une recommandation positive d’ETS pour le remboursement représente une étape importante vers le financement public pour traiter les patients admissibles atteints de ce trouble hépatique rare...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo - Label covers broad range of PFIC...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p<0.0001) - Data are the first to demonstrate a...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.94	-7.60486083889	25.51	26.015	23.29	363813	24.40559461	CS
4	-3.66	-13.441057657	27.23	27.41	23.29	450986	25.31712988	CS
12	-2.93	-11.0566037736	26.5	30.23	23.29	507543	26.97900427	CS
26	-4.27	-15.3376436782	27.84	35.56	23.29	593822	28.73418848	CS
52	-2.42	-9.31127356676	25.99	35.56	23.29	560022	28.30172355	CS
156	5.15	27.9587404995	18.42	35.56	12.82	354022	24.905294	CS
260	10.57	81.3076923077	13	35.56	6.5126	278604	23.54485494	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AGBAAGBA Group Holding Ltd	$ 1.02 (155.00%)	122.88M
ISPCiSpecimen Inc	$ 0.437 (105.16%)	37.44M
TIRXTian Ruixiang Holdings Ltd	$ 0.7898 (62.93%)	58.67M
XPONExpion360 Inc	$ 3.12 (61.66%)	16.63M
BNTCBenitec Biopharma Limited	$ 6.99 (45.63%)	3.51M
WISAWiSA Technologies Inc	$ 5.89 (-36.32%)	16.09M
SPCBSuperCom Ltd	$ 0.24 (-33.31%)	8.57M
EDBLEdible Garden AG Inc	$ 4.52 (-32.13%)	698.17k
MRNOMurano Global Investments PLC	$ 7.22 (-31.24%)	123.91k
AILEiLearningEngines Holdings Inc	$ 7.11 (-28.90%)	53.08k
SINTSiNtx Technologies Inc	$ 0.0396 (6.17%)	438.98M
SQQQProShares UltraPro Short QQQ	$ 12.07 (1.77%)	172.66M
AGBAAGBA Group Holding Ltd	$ 1.02 (155.00%)	122.88M
GGEGreen Giant Inc	$ 0.0362 (23.76%)	96.91M
TSLATesla Inc	$ 149.93 (-3.55%)	96.1M